KRAS and colorectal carcinoma: After establishing the potent inhibitory effect of SLC25A21 on PI3K/AKT and RAF/ERK activity in KRAS-mutant CRC, we hypothesized that SLC25A21 affects the sensitivity of KRAS-mutant cells to anti-EGFR antibody therapy in CRC.